Evaluation of Serum Interleukin-6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results from a French National Multicenter Cohort

Arthritis Care and Research

Volumn 67, Issue 7, 2015, Pages 905-912

  Baillet, Athan ^a   Gossec, Laure ^b   Paternotte, Simon ^c   Etcheto, Adrien ^c   Combe, Bernard ^d   Meyer, Olivier ^c   Mariette, Xavier ^e   Gottenberg, Jacques Eric ^f   Dougados, Maxime ^c  

^a CNRS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e BICÊTRE HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INTERLEUKIN 6; RHEUMATOID FACTOR; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; FEMALE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SMOKING; SYNOVITIS; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; EVALUATION STUDY; FOLLOW UP; FRANCE; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SYNOVITIS;

EID: 84932647996     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22513     Document Type: Article

References (48)

1. Knudsen LS, Ostergaard M, Baslund B, Narvestad E, Petersen J, Nielsen HJ, et al., Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol 2006; 35: 489-91.
2. Vastesaeger N, Xu S, Aletaha D, St.Clair EW, Smolen JS., A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1114-21.
3. Smolen JS, Avila JC, Aletaha D., Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012; 71: 687-93.
4. Colebatch AN, Edwards CJ, Ostergaard M, van der Heijde D, Balint PV, D'Agostino MA, et al., EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013; 72: 804-14.
5. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP., Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002; 46: 2034-8.
6. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y., Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995; 34: 321-5.
7. Straub RH, Gluck T, Cutolo M, Georgi J, Helmke K, Scholmerich J, et al., The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford) 2000; 39: 624-31.
8. Gottenberg JE, Dayer JM, Lukas C, Ducot B, Chiocchia G, Cantagrel A, et al., Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 2012; 71: 1243-8.
9. Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daures JP, Dougados M, et al., The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007; 74: 440-5.
10. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR., The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006; 54: 1117-21.
11. Thompson DK, Huffman KM, Kraus WE, Kraus VB., Critical appraisal of four IL-6 immunoassays. PloS ONE 2012; 7: e30659.
12. Devauchelle-Pensec V, Josseaume T, Samjee I, Dougados M, Combe B, Saraux A., Ability of oblique foot radiographs to detect erosions in early arthritis: results in the ESPOIR cohort. Arthritis Rheum 2008; 59: 1729-34.
13. Funck-Brentano T, Etchepare F, Joulin SJ, Gandjbakch F, Pensec VD, Cyteval C, et al., Benefits of ultrasonography in the management of early arthritis: a cross-sectional study of baseline data from the ESPOIR cohort. Rheumatology (Oxford) 2009; 48: 1515-9.
14. Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D'Agostino MA, et al., Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005; 32: 2485-7.
15. Stone M, Bergin D, Whelan B, Maher M, Murray J, McCarthy C., Power Doppler ultrasound assessment of rheumatoid hand synovitis. J Rheumatol 2001; 28: 1979-82.
16. Fain JN., Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm 2010; 2010: 513948.
17. Klein-Wieringa IR, van der Linden MP, Knevel R, Kwekkeboom JC, van Beelen E, Huizinga TW, et al., Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2011; 63: 2567-74.
18. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, et al., The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167: 332-44.
19. Kirwan JR., The relationship between synovitis and erosions in rheumatoid arthritis. Br J Rheumatol 1997; 36: 225-8.
20. Van der Heide A, Remme CA, Hofman DM, Jacobs JW, Bijlsma JW., Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995; 38: 1466-74.
21. Dougados M, Devauchelle-Pensec V, Ferlet JF, Jousse-Joulin S, D'Agostino MA, Backhaus M, et al., The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 2013; 72: 665-71.
22. Foltz V, Gandjbakhch F, Etchepare F, Rosenberg C, Tanguy ML, Rozenberg S, et al., Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum 2012; 64: 67-76.
23. Dohn UM, Ejbjerg B, Boonen A, Hetland ML, Hansen MS, Knudsen LS, et al., No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 2011; 70: 252-8.
24. Boyesen P, Haavardsholm EA, Ostergaard M, van der Heijde D, Sesseng S, Kvien TK., MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 2011; 70: 428-33.
25. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al., Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95.
26. Dain L, Braun-Moscovici Y, Baum E, Nahir AM, Hoffer E., Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab. Clin Exp Rheumatol 2006; 24: 38-44.
27. Szalai AJ, van Ginkel FW, Wang Y, McGhee JR, Volanakis JE., Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J Immunol 2000; 165: 1030-5.
28. Fischetti F, Durigutto P, Macor P, Marzari R, Carretta R, Tedesco F., Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. Arthritis Rheum 2007; 56: 1187-97.
29. Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP, et al., Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 2002; 46: 2476-85.
30. Sadik CD, Kim ND, Iwakura Y, Luster AD., Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcγR signaling. Proc Natl Acad Sci U S A 2012; 109: E3177-85.
31. De Vries-Bouwstra JK, Goekoop-Ruiterman YP, Wesoly J, Hulsmans HJ, de Craen AJ, Breedveld FC, et al., Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage. Ann Rheum Dis 2007; 66: 1033-7.
32. Pettit AR, Weedon H, Ahern M, Zehntner S, Frazer IH, Slavotinek J, et al., Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 1243-55.
33. Knevel R, van Nies JA, le Cessie S, Huizinga TW, Brouwer E, van der Helm-van Mil AH., Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis [letter]. Ann Rheum Dis 2013; 72: 307-8.
34. Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D., The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum 2008; 58: 718-29.
35. Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X., Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009; 11: R114.
36. Combe B, Rincheval N, Benessiano J, Berenbaum F, Cantagrel A, Daures JP, et al., Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol 2013; 40: 1650-7.
37. Choe JY, Park KY, Park SH, Lee SI, Kim SK., Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res Ther 2013; 15: R26.
38. Krabbe KS, Pedersen M, Bruunsgaard H., Inflammatory mediators in the elderly. Exp Gerontol 2004; 39: 687-99.
39. Zhou X, Fragala MS, McElhaney JE, Kuchel GA., Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care 2010; 13: 541-7.
40. Knudsen LS, Christensen IJ, Lottenburger T, Svendsen MN, Nielsen HJ, Nielsen L, et al., Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 2008; 13: 59-78.
41. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Follett H, Kales A, et al., Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004; 89: 2119-26.
42. Barratt RA, Bowens SL, McCune SK, Johannessen JN, Buckman SY., The critical path initiative: leveraging collaborations to enhance regulatory science. Clin Pharmacol Ther 2012; 91: 380-3.
43. Lekander M, Elofsson S, Neve IM, Hansson LO, Unden AL., Self-rated health is related to levels of circulating cytokines. Psychosom Med 2004; 66: 559-63.
44. Overman CL, Bossema ER, van Middendorp H, Wijngaards-de Meij L, Verstappen SM, Bulder M, et al., The prospective association between psychological distress and disease activity in rheumatoid arthritis: a multilevel regression analysis. Ann Rheum Dis 2012; 71: 192-7.
45. Cannon JG, van der Meer JW, Kwiatkowski D, Endres S, Lonnemann G, Burke JF, et al., Interleukin-1 β in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 1988; 7: 457-67.
46. Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS., Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev 2008; 17: 3450-6.
47. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V., Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-α and leptin. Cytokine 2000; 12: 1712-6.
48. Hosnijeh FS, Krop EJ, Portengen L, Rabkin CS, Linseisen J, Vineis P, et al., Stability and reproducibility of simultaneously detected plasma and serum cytokine levels in asymptomatic subjects. Biomarkers 2010; 15: 140-8.